# Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy

> clinical trial · VERIFIED · 2026-08-13

Status: NOT_YET_RECRUITING · Sponsor: BreakBio Corp · Condition: Triple-Negative Breast Cancer (TNBC)

- Company: BreakBio Corp
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT07762703

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.